(Q66082694)

English

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma (English)

0 references

0 references

0 references

22 August 2016

0 references

end time

August 2019

0 references

number of participants

180

0 references

research intervention

paclitaxel

0 references

clinical trial phase

phase II clinical trial

0 references

research site

BC Cancer Agency

0 references

Queen Elizabeth II Health Sciences Centre - Victoria General

0 references

University of Toronto

0 references

CancerCare Manitoba

0 references

McMaster University

0 references

Centre hospitalier universitaire de Sherbrooke

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02879318

0 references

(Q66082694)

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)